MAY 28, 2020 8:30 AM PDT

Trial for Arthritis Drug with Remdesivir to Beat COVID-19

WRITTEN BY: Annie Lennon

Montefiore Health System and Albert Einstein College of Medicine in New York have teamed up to see how well remdesivir, a drug already approved for COVID-19 treatment, works with an anti-inflammatory drug known as baricitinib against the virus. 

Preliminary results from clinical trials with remdesivir have shown that the drug is able to reduce recovery times from COVID-19 from 15 days to 11 days. Of the 1,063 patients involved in that trial, 91 were from either Montefiore or Einstein hospitals. 

Expanding on these results, doctors and researchers between these hospitals are studying whether remdesivir in combination with baricitinib can yield even better results. Baricitinib is so far known for reducing inflammation linked to rheumatoid arthritis. The researchers' goal is to determine whether the drug, when taken with remdesivir, reduces or prevents cytokine storms (excessive inflammation), which can overwhelm a patient's lungs and other organs, eventually leading to death. 

To do so, they are conducting a placebo-controlled, double-blind, randomized trial for the drug combination. Patients selected for the trial should be hospitalized with a confirmed COVID-19 diagnosis and lung complications, including abnormal chest X-rays, pneumonia, and need of a mechanical ventilator to breathe. While all patients will receive remdesivir intravenously for up to 10 days, half of the patients will be given baricitinib by mouth, and the other half an identical placebo, for up to two weeks. 

"What concerns us is that in some people the immune response to coronavirus can be more deadly than the infection itself, and there is no known treatment for this yet," says Barry Zingman, one of the study's authors also involved in the original remdesivir study. 

"Including baricitinib in our trial may reduce COVID-19-related inflammation and combining baricitinib with remdesivir may yield an even more effective treatment option for people most severely affected by this illness." 


Sources: Science Daily, News Medical

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
NOV 28, 2022
Neuroscience
Modified 'Bath Salts' Hold Potential to Treat Depression
Modified 'Bath Salts' Hold Potential to Treat Depression
Experimental synthetic drugs may treat depression and anxiety-related disorders with few adverse side effects. The corre ...
NOV 29, 2022
Drug Discovery & Development
75g Kale Per Day Could Keep Bone Fractures Away
75g Kale Per Day Could Keep Bone Fractures Away
Vitamin K1- a nutrient found in leafy greens like kale, cabbage, and spinach- may help reduce bone fracture risk in elde ...
JAN 05, 2023
Cancer
Unraveling the link between cancer and circadian rhythm
Unraveling the link between cancer and circadian rhythm
All organisms have a circadian rhythm. In plants, for example, circadian rhythm helps sense light, temperature, length o ...
JAN 06, 2023
Drug Discovery & Development
Shellfish - the new method to prevent unwanted pregnancies
Shellfish - the new method to prevent unwanted pregnancies
A sugar that is created by shellfish may be the next best way to prevent unwanted pregnancies.  According to a 2022 ...
JAN 31, 2023
Plants & Animals
Choosing the Right Bead Mill Homogenization Technology for your Laboratory
Choosing the Right Bead Mill Homogenization Technology for your Laboratory
Bead mill homogenization is a fast technology for automatically preparing a wide variety of samples – up to 96 in ...
JAN 18, 2023
Technology
Artificial pancreas for type 2 diabetes management
Artificial pancreas for type 2 diabetes management
Type 2 diabetes is an increasingly common condition around the globe, affecting over 400 million people. In type 2 diabe ...
Loading Comments...